Boehringer Ingelheim has made its first investment from its corporate venturing fund launched in March in Okairòs, a Switzerland-based drug development company, which has raised €16m ($20.5m) in its series B round. 

The financing was led by venture capital firm Versant Ventures and joined by the €100m Boehringer Ingelheim Venture Fund. All existing investors from Okairòs’ €7.2m series A round in 2007 reinvested. The A round was led by VCs Life Science Partners and BioMedPartners which were joined by local…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?